BioRem Inc. is set to report its first-quarter financial results on May 27, 2026, following a strong performance last year with record revenues and a substantial order backlog. Investors are eager to see how these factors translate into earnings for the quarter ending March 31.
BioRem Inc. (BRM.V) will release its financial results for the first quarter of 2026 before the market opens on May 27. The company has reported a record order backlog of CA$77 million and a 44% increase in revenue for this quarter. However, the earnings calendar lacks specific EPS figures, leaving investors looking for clarity on profitability.
Advertisement
BioRem Inc.
BRM.V
BRM.V
BioRem Inc.
WealthAwesomeAdvertisement
Market cap
$63.15M
P/E
11.4x
52W high
$3.89
52W low
$1.87
1W change
+5.71%
Beta
0.85
Analyst Price Targets
Based on analyst covering BRM
Wall Street analysts forecast BRM stock price to rise 15.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$4.50
+15.7% Upside
Current Price
C$3.89
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BRM's historical volatility
30-Day Vol
55.8%
Annualized
90-Day Vol
53.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$4.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.13 | C$3.41 – C$5.01 |
| 60 trading days | C$4.38 | C$3.34 – C$5.75 |
| 90 trading days | C$4.65 | C$3.33 – C$6.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With a solid order backlog and revenue growth, BioRem Inc. seems well-positioned for long-term growth, though clarity on earnings will be crucial for investor confidence.
What BioRem's Order Backlog Means for Future Earnings
BioRem's reported order backlog of CA$77 million positions the company for potential revenue growth, but without clear EPS figures, the market will be watching closely to see how this translates into profitability in the upcoming report. The forward P/E ratio of 10.44x suggests that investors are expecting some growth, but clarity on earnings will be key to maintaining confidence.
Advertisement
Bull case
- Strong Backlog: The reported order backlog of CA$77 million shows strong demand for BioRem's services, indicating potential for continued revenue growth.
- Positive Revenue Growth: A 44% increase in revenue for the quarter highlights the company's operational strength and market position.
- Attractive Valuation: With a P/E ratio of 11.48x, BioRem might be a good entry point for value-focused investors, especially given its profit margin of 11.21%.
Bear case
- Lack of EPS Guidance: The absence of EPS figures creates uncertainty about profitability, which could lead to stock price volatility.
- Market Sensitivity: As a smaller company with a market cap of CA$50.33 million, BioRem may be more vulnerable to market fluctuations and investor sentiment.
- Dependence on Backlog: While a large order backlog is promising, it needs to convert into actual revenue and profits to keep investors interested.
BioRem Inc. (BRM.V)
Overview: BioRem Inc. specializes in environmental technology solutions, focusing on air and water treatment systems. The company is based in Canada and serves a variety of industries. What the screen shows: Currently, BioRem's stock is trading at CA$3.54 with a market cap of CA$50.33 million. The company has seen a 1-week increase of about 2%. Risks and watch items: Investors should be aware of potential volatility due to the lack of EPS guidance and the company's reliance on converting its order backlog into actual revenue. Additionally, market sensitivity could impact stock performance.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
